ProPhase Labs, Inc. Deferred Revenue
ProPhase Labs, Inc. (PRPH) had Deferred Revenue of $2.38 million as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2024-03-29
- 2023-12-31: Deferred Revenue, Current $2.38M.
- 2023-09-30: Deferred Revenue, Current $2.45M.
- 2023-06-30: Deferred Revenue, Current $2.25M.
- 2023-03-31: Deferred Revenue, Current $2.84M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2023-12-31 | $2.38M 10-K · filed 2024-03-29 |
| 2023-09-30 | $2.45M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $2.25M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $2.84M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $2.50M 10-K · filed 2024-03-29 |
| 2022-09-30 | $2.96M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.43M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $2.25M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $2.03M 10-K · filed 2023-03-29 |
| 2021-09-30 | $1.52M 10-Q · filed 2021-11-12 |
| 2020-12-31 | $169.00K 10-K · filed 2022-03-31 |
| 2018-09-30 | $57.00K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $52.00K 10-Q · filed 2018-08-20 |
| 2018-03-31 | $91.00K 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |